RANKL/RANK pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of EGFR and c-Src

References

• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• WagnerADGrotheWHaertingJKleberGGrotheyAFleigWEChemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate dataJ Clin Oncol200624182903290916782930
   PubMed Web of Science ®Google Scholar
• AtmacaAWernerDPauligkCThe prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancerBMC Cancer20121252423153332
   PubMed Web of Science ®Google Scholar
• KimJSKimMAKimTMBiomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survivalBr J Cancer2009100573273819259093
   PubMed Web of Science ®Google Scholar
• LordickFKangYKChungHCCapecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trialLancet Oncol201314649049923594786
   PubMed Web of Science ®Google Scholar
• WaddellTChauICunninghamDEpirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialLancet Oncol201314648148923594787
   PubMed Web of Science ®Google Scholar
• YanoSWangWLiQHepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutationsCancer Res200868229479948719010923
   PubMed Web of Science ®Google Scholar
• MorgilloFKimWYKimESCiardielloFHongWKLeeHYImplication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinibClin Cancer Res20071392795280317473213
   PubMed Web of Science ®Google Scholar
• YiTLeeHLChaJHEpidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signalingJ Cell Physiol2008217240942218543257
   PubMedGoogle Scholar
• SantiniDPerroneGRoatoIExpression pattern of receptor activator of NFkappaB (RANK) in a series of primary solid tumors and related bone metastasesJ Cell Physiol2011226378078420857484
   PubMed Web of Science ®Google Scholar
• ArmstrongAPMillerREJonesJCZhangJKellerETDougallWCRANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genesProstate20086819210418008334
   PubMed Web of Science ®Google Scholar
• JonesDHNakashimaTSanchezOHRegulation of cancer cell migration and bone metastasis by RANKLNature2006440708469269616572175
   PubMed Web of Science ®Google Scholar
• ZhangLTengYZhangYC-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathwayOncol Lett20123239540022740919
   PubMedGoogle Scholar
• SongNLiuSZhangJCetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cellsInt J Mol Sci20141545838585124714091
   PubMedGoogle Scholar
• LiHXuLLiCUbiquitin ligase Cbl-b represses IGF-I-induced epithelial mesenchymal transition via ZEB2 and microRNA-200c regulation in gastric cancer cellsMol Cancer20141313624885194
   PubMedGoogle Scholar
• LordickFLuberBLorenzenSCetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)Br J Cancer2010102350050520068568
   PubMed Web of Science ®Google Scholar
• MoehlerMMuellerATrarbachTCetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II studyAnn Oncol20112261358136621119032
   PubMed Web of Science ®Google Scholar
• PintoCDi FabioFBaroneCPhase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)Br J Cancer200910181261126819773760
   PubMed Web of Science ®Google Scholar
• PintoCDi FabioFSienaSPhase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)Ann Oncol200718351051717164226
   PubMed Web of Science ®Google Scholar
• TsubakiMKomaiMFujimotoSActivation of NF-kappaB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell linesJ Exp Clin Cancer Res2013326224011086
   PubMedGoogle Scholar
• WangJLiuYWangLSunXWangYClinical prognostic significance and pro-metastatic activity of RANK/RANKL via the AKT pathway in endometrial cancerOncotarget2016755564557526734994
   PubMedGoogle Scholar
• Odero-MarahVAWangRChuGReceptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cellsCell Res200818885887018645583
   PubMed Web of Science ®Google Scholar
• SchramekDLeibbrandtASiglVOsteoclast differentiation factor RANKL controls development of progestin-driven mammary cancerNature201046873209810220881962
   PubMed Web of Science ®Google Scholar
• Gonzalez-SuarezEJacobAPJonesJRANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesisNature2010468732010310720881963
   PubMed Web of Science ®Google Scholar
• BiscardiJSMaaMCTiceDACoxMELeuTHParsonsSJc-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor functionJ Biol Chem1999274128335834310075741
   PubMed Web of Science ®Google Scholar
• StoverDRBeckerMLiebetanzJLydonNBSrc phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alphaJ Biol Chem19952702615591155977797556
   PubMedGoogle Scholar
• LiRZhangKPenedoTLThe RANK pathway in advanced breast cancer: does Src play a role?Appl Immunohistochem Mol Morphol2016241425026200837
   PubMedGoogle Scholar
• TanWZhangWStrasnerAFibroblast-recruited, tumor-infiltrating CD4+ T cells stimulate mammary cancer metastasis through RANKL-RANK signalingNature2011470733554855321326202
   PubMed Web of Science ®Google Scholar
• OhnoSTachibanaMFujiiTUedaSKubotaHNagasueNRole of stromal collagen in immunomodulation and prognosis of advanced gastric carcinomaInt J of Cancer200297677077411857352
   PubMedGoogle Scholar